Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs

November 3rd 2025

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma

November 3rd 2025

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

Lifileucel Displays Antitumor Activity in Advanced Nonsquamous NSCLC

November 3rd 2025

Lifileucel was deemed safe and active in patients with previously treated, advanced nonsquamous NSCLC without certain actionable genetic mutations.

FDA Approval of Zongertinib Marks a Targeted Advancement for Patients With HER2-Mutant NSCLC

November 3rd 2025

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

New ADC Data Underscore Progress and Highlight Challenges in HER2+ Breast Cancer and TNBC Management

November 2nd 2025

In a recent Peer Exchange, breast cancer experts discussed updates from ESMO 2025, including practice-informing data with antibody-drug conjugates.

Revisit Every OncLive On Air Episode From October 2025

November 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in October 2025.

Dr Jhaveri on the Association Between ADCs and Ocular Toxicities in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses ocular toxicities that can be seen with the use of ADCs when treating patients with breast cancer.

Dr Stock on the Multifaceted Role of Molecular Testing in Ph+ ALL

October 31st 2025

Wendy Stock, MD, discussed the role of molecular testing in Ph-positive ALL and best practices for implementing this testing across clinical scenarios.

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Dr Dent on the Efficacy of First-Line Dato-DXd in TNBC

October 31st 2025

Rebecca Dent, MD, MSc, FRCP, discusses data from the TROPION-Breast02 trial of frontline Dato-DXd vs chemotherapy in locally recurrent metastatic TNBC.

Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced Breast Cancer

October 31st 2025

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Dr Sweis on Next Steps for the Investigation of XmAb819 in RCC and Beyond

October 31st 2025

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses management strategies for ocular toxicities and other ADC-related adverse effects in breast cancer.

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Dr Hurvitz on Data With Gedatolisib-Based Regimens in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, shares efficacy and safety data from the VIKTORIA-1 study in endocrine-resistant HR-positive breast cancer.

Dr Hurvitz on the Rationale for Targeting PI3K and mTOR in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.

Dr Jänne on Key Areas of Ongoing Debate in EGFR+ NSCLC

October 30th 2025

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC

October 30th 2025

Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.

Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025

October 30th 2025

Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.